Sign In
Buy VNDA
$5.10
-0.0800 (-1.54%)
At Close: Jul 31, 2026
Vanda Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:VNDA)
01:32am, Tuesday, 24'th Feb 2026
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA - Get Free Report) was the target of some unusual options trading activity on Monday. Traders purchased 13,610 call options on the stock. This is an increase o
Vanda Pharmaceuticals: Soaring On Bysanti Approval, But You Shouldn't Feel Dizzy
02:51pm, Monday, 23'rd Feb 2026
Vanda Pharmaceuticals Inc. has received FDA approval for BYSANTI, a new atypical antipsychotic targeting bipolar I disorder and schizophrenia. VNDA now markets five products, but BYSANTI's differentia
Vanda Pharmaceuticals stock's explosive rally may be more hype than substance
10:28am, Monday, 23'rd Feb 2026
Vanda Pharmaceuticals (NASDAQ: VNDA) opened some 45% higher today after the biotech firm said it has received the FDA's approval for its treatment of schizophrenia and bipolar I disorder. The BYSANTI
Vanda Pharmaceuticals FDA Approval Dawns A New Era For Bipolar And Schizophrenia Treatment
09:00am, Monday, 23'rd Feb 2026
Vanda Pharmaceuticals (NASDAQ: VNDA) shares are trading higher during the premarket session on Monday following the announcement of FDA approval for Bysanti (milsaperidone), a new treatment for bipola
U.S. stock futures fell on Monday after closing higher on Friday. Futures of all the major benchmark indices were negative after the Supreme Court struck down federal tariffs imposed by President Dona
US FDA approves Vanda's psychiatric drug
06:03pm, Friday, 20'th Feb 2026
The U.S. Food and Drug Administration has approved Vanda Pharmaceutical's drug for the treatment of two serious mental health conditions, the company said on Friday.
WASHINGTON, Feb. 20, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™ (milsaperidone) tablets, a
Vanda Pharma: High Risk, Heavily Discounted - Stock Ahead Of PDUFA This Week
08:09am, Thursday, 19'th Feb 2026
Vanda Pharmaceuticals reported weak FY25 results, with a GAAP EPS miss and heavy losses, despite 9% revenue growth driven by Fanapt. VNDA's valuation is deeply discounted, trading at 1.4x forward sale
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Consensus Recommendation of “Moderate Buy” from Analysts
03:29am, Thursday, 19'th Feb 2026
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA - Get Free Report) has received an average rating of "Moderate Buy" from the seven brokerages that are currently covering the firm, MarketBeat Ratings reports.
Vanda Pharmaceuticals Inc. (VNDA) Q4 2025 Earnings Call Transcript
10:27am, Saturday, 14'th Feb 2026
Vanda Pharmaceuticals Inc. (VNDA) Q4 2025 Earnings Call Transcript
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
06:56pm, Thursday, 12'th Feb 2026
NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are adv
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates
06:15pm, Wednesday, 11'th Feb 2026
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $2.18. This compares to a loss of $0.08 per share a year ago.
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
04:01pm, Wednesday, 11'th Feb 2026
Full year 2025 Fanapt® net product sales increased by 24% to $117.3 million compared to full year 2024 Full year 2025 total revenues increased by 9% to $216.1 million compared to full year 2024 NERE
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
06:01pm, Wednesday, 04'th Feb 2026
Conference Call and Webcast to Follow WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
01:40pm, Tuesday, 03'rd Feb 2026
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA). Such inve
